Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,502,000 | 2,913,000 | 2,329,000 | 865,000 | 952,000 |
| Receivables | 2,501,000 | 2,400,000 | 2,304,000 | 2,228,000 | 2,101,000 |
| Inventories | 2,753,000 | 2,608,000 | 2,561,000 | 2,484,000 | 2,404,000 |
| Other current assets | 673,000 | 755,000 | 672,000 | 622,000 | 740,000 |
| TOTAL | $8,761,000 | $8,991,000 | $8,185,000 | $6,514,000 | $6,504,000 |
| Non-Current Assets | |||||
| PPE Net | 3,072,000 | 2,951,000 | 2,897,000 | 2,859,000 | 2,635,000 |
| Intangibles | 20,787,000 | 19,814,000 | 20,200,000 | 20,390,000 | 19,457,000 |
| Other Non-Current Assets | 5,458,000 | 5,352,000 | 5,388,000 | 5,372,000 | 5,445,000 |
| TOTAL | $29,317,000 | $28,117,000 | $28,485,000 | $28,621,000 | $27,537,000 |
| Total Assets | $38,078,000 | $37,108,000 | $36,669,000 | $35,136,000 | $34,043,000 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,652,000 | 1,580,000 | 1,085,000 | 531,000 | 513,000 |
| Accounts payable and accrued liabilities | 907,000 | 906,000 | 921,000 | 942,000 | 929,000 |
| Accrued Expenses | 2,460,000 | 2,320,000 | 2,083,000 | 2,646,000 | 2,255,000 |
| Other current liabilities | 891,000 | 770,000 | 827,000 | 814,000 | 882,000 |
| TOTAL | $5,910,000 | $5,576,000 | $4,916,000 | $4,933,000 | $4,579,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 9,233,000 | 8,991,000 | 9,534,000 | 8,571,000 | 8,386,000 |
| Other Non-Current Liabilities | 1,841,000 | 1,802,000 | 1,920,000 | 1,967,000 | 1,858,000 |
| TOTAL | $11,212,000 | $10,923,000 | $11,585,000 | $10,672,000 | $10,335,000 |
| Total Liabilities | $17,122,000 | $16,499,000 | $16,501,000 | $15,606,000 | $14,914,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,473,827 | 1,472,626 | 1,470,180 | 1,467,096 | 1,464,983 |
| Common Shares | 17,000 | 17,000 | 17,000 | 17,000 | 17,000 |
| Retained earnings | 2,107,000 | 1,639,000 | 1,314,000 | 819,000 | 315,000 |
| Other shareholders' equity | 120,000 | 401,000 | 375,000 | 298,000 | 475,000 |
| TOTAL | $20,956,000 | $20,609,000 | $20,168,000 | $19,530,000 | $19,129,000 |
| Total Liabilities And Equity | $38,078,000 | $37,108,000 | $36,669,000 | $35,136,000 | $34,043,000 |